美国私人保险男性非转移性前列腺癌治疗费用。

IF 2.6 3区 综合性期刊 Q1 MULTIDISCIPLINARY SCIENCES
PLoS ONE Pub Date : 2025-05-30 eCollection Date: 2025-01-01 DOI:10.1371/journal.pone.0324902
Ashley J Housten, Su-Hsin Chang, Hannah E Rice, Allison J L'Hotta, Eric H Kim, Bettina F Drake, Joanna L Buss, Mary C Politi
{"title":"美国私人保险男性非转移性前列腺癌治疗费用。","authors":"Ashley J Housten, Su-Hsin Chang, Hannah E Rice, Allison J L'Hotta, Eric H Kim, Bettina F Drake, Joanna L Buss, Mary C Politi","doi":"10.1371/journal.pone.0324902","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Our objective was to quantify the cumulative total and out-of-pocket (OOP) costs for 3 non-metastatic prostate cancer treatment modalities: radiation, surgery, and conservative management at intervals of 1-, 3-, and 5-years post-diagnosis. We predicted these cumulative costs for a typical patient to improve cost transparency, facilitate conversations about potential costs, and to help advance non-metastatic prostate cancer cost evaluation.</p><p><strong>Methods: </strong>We used Merative™ MarketScan® Commercial Database data from 2007-2020. The cumulative total costs evaluated from the healthcare sector perspective were patient, clinician, and system/facility costs. We used descriptive statistics to summarize the sociodemographic characteristics of the cohort and a multivariable regression model to estimate the association between each treatment option (radiation, surgery, conservative management) and costs with inverse probability of treatment weighting (IPTW) to account for potential selection bias. We then predicted total and OOP costs defined by sample mode characteristics.</p><p><strong>Results: </strong>This cohort included 74,324 patients. Cumulative total and OOP costs were significantly higher for radiation (p < 0.0001) and for surgery (p < 0.0001) at Years 1, 3, and 5 compared to conservative management. For a typical patient, total cumulative cost estimates for conservative management at Years 1/3/5 were: $15,896/$33,436/$48,110 and the cumulative patient OOP costs were: $2,003/$4,540/$6,621. The cumulative total costs for surgery at Years 1/3/5 were: $38,348/$49,424/$60,885 and the cumulative OOP costs were: $2,980/$5,255/$7,221. The cumulative total costs for radiation at Years 1/3/5 were: $65,397/$77,859/$91,497 and the cumulative OOP costs were: $3,151/$5,481/$7,504.</p><p><strong>Conclusions: </strong>For all years, the cumulative costs of radiation were highest, followed by surgery and conservative management, respectively. Radiation as the first treatment modality had higher costs compared to surgery and conservative management at the 3 time points.</p><p><strong>Impact: </strong>These cost estimates support non-metastatic prostate cancer treatment related cost transparency. These estimates can help researchers evaluate costs and facilitate patient-clinician cost conversations.</p>","PeriodicalId":20189,"journal":{"name":"PLoS ONE","volume":"20 5","pages":"e0324902"},"PeriodicalIF":2.6000,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12124492/pdf/","citationCount":"0","resultStr":"{\"title\":\"Costs of non-metastatic prostate cancer treatment among privately insured men in the United States.\",\"authors\":\"Ashley J Housten, Su-Hsin Chang, Hannah E Rice, Allison J L'Hotta, Eric H Kim, Bettina F Drake, Joanna L Buss, Mary C Politi\",\"doi\":\"10.1371/journal.pone.0324902\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Our objective was to quantify the cumulative total and out-of-pocket (OOP) costs for 3 non-metastatic prostate cancer treatment modalities: radiation, surgery, and conservative management at intervals of 1-, 3-, and 5-years post-diagnosis. We predicted these cumulative costs for a typical patient to improve cost transparency, facilitate conversations about potential costs, and to help advance non-metastatic prostate cancer cost evaluation.</p><p><strong>Methods: </strong>We used Merative™ MarketScan® Commercial Database data from 2007-2020. The cumulative total costs evaluated from the healthcare sector perspective were patient, clinician, and system/facility costs. We used descriptive statistics to summarize the sociodemographic characteristics of the cohort and a multivariable regression model to estimate the association between each treatment option (radiation, surgery, conservative management) and costs with inverse probability of treatment weighting (IPTW) to account for potential selection bias. We then predicted total and OOP costs defined by sample mode characteristics.</p><p><strong>Results: </strong>This cohort included 74,324 patients. Cumulative total and OOP costs were significantly higher for radiation (p < 0.0001) and for surgery (p < 0.0001) at Years 1, 3, and 5 compared to conservative management. For a typical patient, total cumulative cost estimates for conservative management at Years 1/3/5 were: $15,896/$33,436/$48,110 and the cumulative patient OOP costs were: $2,003/$4,540/$6,621. The cumulative total costs for surgery at Years 1/3/5 were: $38,348/$49,424/$60,885 and the cumulative OOP costs were: $2,980/$5,255/$7,221. The cumulative total costs for radiation at Years 1/3/5 were: $65,397/$77,859/$91,497 and the cumulative OOP costs were: $3,151/$5,481/$7,504.</p><p><strong>Conclusions: </strong>For all years, the cumulative costs of radiation were highest, followed by surgery and conservative management, respectively. Radiation as the first treatment modality had higher costs compared to surgery and conservative management at the 3 time points.</p><p><strong>Impact: </strong>These cost estimates support non-metastatic prostate cancer treatment related cost transparency. These estimates can help researchers evaluate costs and facilitate patient-clinician cost conversations.</p>\",\"PeriodicalId\":20189,\"journal\":{\"name\":\"PLoS ONE\",\"volume\":\"20 5\",\"pages\":\"e0324902\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-05-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12124492/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PLoS ONE\",\"FirstCategoryId\":\"103\",\"ListUrlMain\":\"https://doi.org/10.1371/journal.pone.0324902\",\"RegionNum\":3,\"RegionCategory\":\"综合性期刊\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"MULTIDISCIPLINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PLoS ONE","FirstCategoryId":"103","ListUrlMain":"https://doi.org/10.1371/journal.pone.0324902","RegionNum":3,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}
引用次数: 0

摘要

背景:我们的目的是量化3种非转移性前列腺癌治疗方式的累积总费用和自付费用(OOP):放射、手术和保守治疗,诊断后间隔1年、3年和5年。我们预测这些典型患者的累积成本,以提高成本透明度,促进潜在成本的对话,并帮助推进非转移性前列腺癌的成本评估。方法:使用2007-2020年Merative™MarketScan®商业数据库数据。从医疗保健部门的角度评估的累积总成本是患者、临床医生和系统/设施成本。我们使用描述性统计来总结队列的社会人口学特征,并使用多变量回归模型来估计每种治疗方案(放疗、手术、保守治疗)与治疗加权逆概率(IPTW)的成本之间的关联,以解释潜在的选择偏倚。然后,我们预测了由样本模式特征定义的总成本和面向对象成本。结果:该队列包括74,324例患者。结论:放疗的累积总费用和全生命周期费用均最高,其次为手术和保守治疗。在3个时间点,放疗作为第一种治疗方式的费用高于手术和保守治疗。影响:这些成本估算支持非转移性前列腺癌治疗相关的成本透明度。这些估算可以帮助研究人员评估成本,并促进患者与临床医生的成本对话。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Costs of non-metastatic prostate cancer treatment among privately insured men in the United States.

Costs of non-metastatic prostate cancer treatment among privately insured men in the United States.

Costs of non-metastatic prostate cancer treatment among privately insured men in the United States.

Costs of non-metastatic prostate cancer treatment among privately insured men in the United States.

Background: Our objective was to quantify the cumulative total and out-of-pocket (OOP) costs for 3 non-metastatic prostate cancer treatment modalities: radiation, surgery, and conservative management at intervals of 1-, 3-, and 5-years post-diagnosis. We predicted these cumulative costs for a typical patient to improve cost transparency, facilitate conversations about potential costs, and to help advance non-metastatic prostate cancer cost evaluation.

Methods: We used Merative™ MarketScan® Commercial Database data from 2007-2020. The cumulative total costs evaluated from the healthcare sector perspective were patient, clinician, and system/facility costs. We used descriptive statistics to summarize the sociodemographic characteristics of the cohort and a multivariable regression model to estimate the association between each treatment option (radiation, surgery, conservative management) and costs with inverse probability of treatment weighting (IPTW) to account for potential selection bias. We then predicted total and OOP costs defined by sample mode characteristics.

Results: This cohort included 74,324 patients. Cumulative total and OOP costs were significantly higher for radiation (p < 0.0001) and for surgery (p < 0.0001) at Years 1, 3, and 5 compared to conservative management. For a typical patient, total cumulative cost estimates for conservative management at Years 1/3/5 were: $15,896/$33,436/$48,110 and the cumulative patient OOP costs were: $2,003/$4,540/$6,621. The cumulative total costs for surgery at Years 1/3/5 were: $38,348/$49,424/$60,885 and the cumulative OOP costs were: $2,980/$5,255/$7,221. The cumulative total costs for radiation at Years 1/3/5 were: $65,397/$77,859/$91,497 and the cumulative OOP costs were: $3,151/$5,481/$7,504.

Conclusions: For all years, the cumulative costs of radiation were highest, followed by surgery and conservative management, respectively. Radiation as the first treatment modality had higher costs compared to surgery and conservative management at the 3 time points.

Impact: These cost estimates support non-metastatic prostate cancer treatment related cost transparency. These estimates can help researchers evaluate costs and facilitate patient-clinician cost conversations.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
PLoS ONE
PLoS ONE 生物-生物学
CiteScore
6.20
自引率
5.40%
发文量
14242
审稿时长
3.7 months
期刊介绍: PLOS ONE is an international, peer-reviewed, open-access, online publication. PLOS ONE welcomes reports on primary research from any scientific discipline. It provides: * Open-access—freely accessible online, authors retain copyright * Fast publication times * Peer review by expert, practicing researchers * Post-publication tools to indicate quality and impact * Community-based dialogue on articles * Worldwide media coverage
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信